Semaglutide vs tirzepatide: how a physician helps you choose
Two names keep coming up. You have read the headlines, scrolled the threads, maybe argued about it with a friend who swears by one of them. Now you want a straight answer: which is better, semaglutide or tirzepatide? Here is the honest version. There is no single winner for everyone. They are built differently, they behave differently in different bodies, and the right pick is a decision you make with a clinician who actually knows your history. Let us walk through what separates them.
The short answer. Tirzepatide acts on two gut hormones; semaglutide acts on one. In head-to-head trial data, tirzepatide produced a higher average weight reduction. But averages are not promises, side-effect profiles differ, and the better medicine is the one that fits your health, your tolerance, and your physician's read. Individual results vary.
- How each drug actually works inside the body
- What the head-to-head trial data shows (and what it does not)
- How the side-effect profiles compare
- The dosing cadence for each, week by week
They are cousins, not twins
Semaglutide is a GLP-1 receptor agonist. Translation: it mimics one of your gut's natural appetite hormones, GLP-1. That hormone tells your brain you are full, and it slows how fast your stomach empties. Eat less, feel satisfied longer. That is the whole engine.
What the head-to-head data actually shows
In the SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, researchers put the two drugs in the same race. They randomly assigned 751 adults with obesity without diabetes to weekly tirzepatide or weekly semaglutide for 72 weeks, then measured the difference.
How the side effects compare
Both carry the same boxed warning about a risk of thyroid C-cell tumors seen in rodent studies, and both list a warning about pancreatitis. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. This is exactly the kind of screening a prescribing clinician does before either drug is on the table. It is not a self-assessment.
Dosing: a slow climb, either way
| Wegovy injection (semaglutide) | Zepbound injection (tirzepatide) | |
|---|---|---|
| Targets | GLP-1 receptor (one) | GLP-1 + GIP receptors (two) |
| How it is taken | Once-weekly injection | Once-weekly injection |
| Label starting dose, prescribed by a clinician | 0.25 mg once weekly for 4 weeks | 2.5 mg once weekly for 4 weeks |
| Dose escalation | Follow the semaglutide product label; escalation may be delayed for tolerability | Increase tirzepatide only after at least 4 weeks on the current dose, if needed and tolerated |
| Maximum tolerated doses studied in SURMOUNT-5 | Semaglutide 1.7 or 2.4 mg weekly | Tirzepatide 10 or 15 mg weekly |
| Head-to-head avg (SURMOUNT-5, 72 wk) | 13.7% | 20.2% |
| Side-effect family | GI (nausea, GI upset) | GI (nausea, GI upset) |
| Main shared warnings | Thyroid C-cell, pancreatitis | Thyroid C-cell, pancreatitis |
What a good comparison should leave you with
That qualified person looks at things a blog never can: your medical history, your other prescriptions, your past tolerance, your goals, and what your insurance or budget actually allows. The drug is one variable. The care around it is the rest.
Your next three steps
That is exactly what a prescribing clinician helps determine, using your history, tolerance, and goals. Trial averages describe groups, not individuals. This article cannot tell you, and any source that claims to without knowing you should be read with caution.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From price shown is the 12-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Weight Loss
Sources
- Eli Lilly and Company. "Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine." May 2025. investor.lilly.com
- Applied Clinical Trials Online. "Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial." May 2025. appliedclinicaltrialsonline.com
- HCPLive. "SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial." May 2025. hcplive.com
- Weill Cornell Medicine Newsroom. "Head-to-Head Trial Compares Weight Loss Drugs." May 2025. news.weill.cornell.edu
- AJMC. "Semaglutide 2.4-mg Injection as a Novel Approach for Chronic Weight Management" (STEP 1 results). ajmc.com
- New England Journal of Medicine. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). 2022. nejm.org
- Eli Lilly and Company. "Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight." investor.lilly.com
- NCBI Bookshelf, StatPearls. "Tirzepatide" (GIP/GLP-1 mechanism). ncbi.nlm.nih.gov
- Springer, Diabetes Therapy. "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist... The SURPASS Clinical Trials." link.springer.com
- Current prescribing information: Wegovy injection Zepbound injection novo-pi.com
- Current prescribing information: Wegovy injection Zepbound injection pi.lilly.com
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. Published May 11, 2025; checked September 15, 2026. nejm.org